Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Felzartamab in Membranous Nephropathy Failing Anti-CD20 Therapy
NCT04893096Phase 2Completed
- Sponsor
- Mario Negri Institute for Pharmacological Research
- Start
- Oct 2021
- Primary completion
- Feb 2025
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of felzartamab in membranous nephropathy (MN), sponsored by Mario Negri Institute for Pharmacological Research. Started Oct 2021; status: completed.
02
Drugs
felzartamab
03
Conditions
membranous nephropathy (MN)
Beyond the preview
Go deeper on NCT04893096.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04893096.